ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2014
Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development.Biomolecules · 2024Review
- Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity.Molecular cancer therapeutics · 2024Article
- Drug targeting of aminopeptidases: importance of deploying a right metal cofactor.Biophysical reviews · 2024Review
- The Development of the Bengamides as New Antibiotics against Drug-Resistant Bacteria.Marine drugs · 2022Review
- Treatment of Acquired Hypothalamic Obesity: Now and the Future.Frontiers in endocrinology · 2022Review
- Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales.Frontiers in pharmacology · 2021Review
- Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders.Clinical medicine insights. Endocrinology and diabetes · 2021Review
- Article
- Covalent Inhibition in Drug Discovery.ChemMedChem · 2019Review
- Redox Signaling by Reactive Electrophiles and Oxidants.Chemical reviews · 2018Review
- Omics Assisted N-terminal Proteoform and Protein Expression Profiling On Methionine Aminopeptidase 1 (MetAP1) Deletion.Molecular & cellular proteomics : MCP · 2018Article
- Comprehensive comparison of MetAP2 tissue and cellular expression pattern in lean and obese rodents.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- Effect of Vitamin D Supplementation on Weight Loss, Glycemic Indices, and Lipid Profile in Obese and Overweight Women: A Clinical Trial Study.International journal of preventive medicine · 2018Article
- A quadratically regularized functional canonical correlation analysis for identifying the global structure of pleiotropy with NGS data.PLoS computational biology · 2017Article
- Common therapeutic target for both cancer and obesity.World journal of biological chemistry · 2017Article
- Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.Advances in pediatrics · 2016Review
- Convertible visceral fat as a therapeutic target to curb obesity.Nature reviews. Drug discovery · 2016Review
- Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Treating morbid obesity in cirrhosis: A quest of holy grail.World journal of hepatology · 2015Review
- Horizons in the Pharmacotherapy of Obesity.Current obesity reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide prevalence of obesity has nearly doubled since 1980. Obesity is the result of interactions among the environmental factors, genetic predisposition, and human behavior. Even modest weight reduction in obese patients provides beneficial health outcomes. For effective weight reduction, a drug should either increase energy expenditure or decrease energy intake without causing serious adverse effects. To overcome lack of efficacy and central nervous system related side effects, exploitation of the peripheral mechanism of anti-obesity action is needed. Inhibition of pathological angiogenesis in adipose tissue is one such peripheral mechanism that has attracted the attention of researchers in this area. Although originally developed as anti-cancer agents, methionine aminopeptidase (MetAP2) inhibitors induce significant and sustained weight reduction. Here, we review preclinical and clinical pharmacology of MetAP2 inhibitors. Beloranib is a prototype MetAP2 inhibitor, and currently in advanced clinical trials for the treatment of obesity. Clinical data of beloranib indicate that MetAP2 inhibitors could be a future treatment option for weight reduction without serious adverse effects. Further clinical data from Phase III trials will add to our growing knowledge of MetAP2 inhibitor potential for anti-obesity therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.